The Latest on the Intracept Procedure

Relievant Medsystems, a privately held medical device company transforming the treatment of Chronic Low Back Pain (CLBP), announced today that new Category I Current Procedural Terminology (CPT) codes for the Intracept Procedure are in effect as of January 1, 2022.

Relievant Medsystems, a privately held medical device company transforming the treatment of Chronic Low Back Pain (CLBP), today announced 24-month results from a Level 1, prospective, randomized, multi-center trial (INTRACEPT) that further validate the safety, effectiveness, and durability of the Intracept® Procedure for patients with vertebrogenic CLBP.

Relievant Medsystems, a privately held medical device company transforming the treatment of Chronic Low Back Pain (CLBP), today announced the Centers for Disease Control and Prevention (CDC) has designated an International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis code specifically for vertebrogenic low back pain.

Relievant Medsystems, a privately held medical device company transforming the treatment of Chronic Low Back Pain (CLBP), announced today the appointment of Dave Amerson to the Company’s Board of Directors.

Relievant Medsystems Announces Publication of New INTRACEPT Trial Data Showing Sustained Relief from Chronic Low Back Pain 12 Months Post-Procedure. Study Results Validate Superiority of Basivertebral Nerve Ablation Compared to Standard Care, With Similar Improvements Demonstrated in Crossover Population.

Relievant Medsystems, a privately held medical device company transforming the treatment of Chronic Low Back Pain (CLBP), announced today the appointment of Tyler Binney as President and Chief Executive Officer.

Relievant Medsystems, a privately‐held medical device company transforming the treatment of Chronic Low Back Pain (CLBP), announced today the launch of Intracept.com – a new website helping educate patients regarding the Intracept Procedure.

Financing to build on significant 2020 commercial momentum following the publication of 5-year data demonstrating the long-term clinical benefits of the Intracept Procedure.

Relievant Medsystems, a privately-held medical device company transforming the treatment of Chronic Low Back Pain (CLBP), today announced the North American Spine Society Journal publication of results from an effectiveness study showing that the significant improvements in function and pain initially reported at an interim analysis of three months following the Intracept Procedure remained significant through one year.

Relievant Medsystems, a privately-held medical device company transforming the treatment of Chronic Low Back Pain (CLBP), today announced European Spine Journal publication of long-term data from the Level I SMART trial showing durability of improvements in pain and function beyond 5 years for patients treated with the Intracept procedure…